Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma 3Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

pembrolizumab 16Bevacizumab 12Carboplatin 10Nivolumab 8Pemetrexed 7Temozolomide 6Standard of Care 6Exercise 6Cetuximab 6durvalumab 5atezolizumab 5Prednisone 5Cyclophosphamide 5abemaciclib 4Paclitaxel 4Doxorubicin 4Dexamethasone 4Cisplatin 4Blood Specimen Collection 4temsirolimus 3enzalutamide 3dostarlimab 3daratumumab 3cabozantinib 3Sunitinib 3Rituximab 3Oxaliplatin 3Metformin 3Leucovorin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × glofitamab × 30 days × Clear all
NCT06634589 2026-06-03

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡